



Endocarditis of Native and Prosthetic Valves, Infections of Cardiac Implantable Devices

Henry F. Chambers, MD
Professor of Medicine, Emeritus
University of California, San Francisco

8/8/2026



Disclosures of Financial Relationships with Relevant Commercial Interests

- Merck – Stock and DSMB member
- Moderna - Stock

Topics for Discussion

- Diagnosis of endocarditis
- Native valve endocarditis
- Culture-negative endocarditis
- Prosthetic valve and device-related infections

Diagnosis of Endocarditis

45 Endocarditis of Native and Prosthetic Devices, and Infections of Pacers and Ventricular Assist Devices

Speaker: Henry Chambers, MD

Question #1

Which one of the following statements is correct?


1. Staphylococcus aureus is the most common cause of bacterial endocarditis
2. Dental procedures carry a substantial risk for streptococcal endocarditis for patients with predisposing cardiac lesions
3. Three-quarters of patients with endocarditis have a known underlying cardiac predisposing condition
4. Fever and a new cardiac murmur are present in the majority of patients with endocarditis

Clinical Signs and Symptoms

Finding	Approximate Prevalence, %
Fever	90
Murmur	70-85
New murmur	50
Worsening old murmur	20
Peripheral stigmata (e.g., Osler's)	20% or less
Heart failure, cardiac complications	20-50
CNS complications	20-40

Arch Intern Med. 2009;169:463-473

Microvascular/Immunologic Phenomena



Microbiology

Organisms	Approximate % of Total
Staphylococci	40-50
S. aureus	30-40
Coag-neg	10
Streptococci	25-30
Viridans group	20
S. gallolyticus	5
Groups B, C, D	5
Enterococcus	10
HACEK	1-2
Culture-negative	3-5

SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION

Arch Intern Med. 2009;169:463; Antimicrob Agents Chemother. 2015;60:1411; Clin Infect Dis. 2018;66:104; Lancet 2016; 387: 882

45 Endocarditis of Native and Prosthetic Devices, and Infections of Pacers and Ventricular Assist Devices

Speaker: Henry Chambers, MD

The 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis: Updating the Modified Duke Criteria

Vance G. Fowler, Jr.^{1,2,3} David T. Durack,¹ Christine Selton-Suty,³ Eugene Athan,⁴ Arnold S. Bayer,^{5,6} Anna Lisa Chamis,¹ Anders Dahl,⁷ Louis DiBernardo,¹ Emanuele Durante-Mangoni,⁸ Xavier Duval,⁹ Claudio Querido Fortes,¹⁰ Emil Fosbol,¹¹ Margaret M. Hannan,¹² Barbara Hasso,¹³ Bruno Hoen,¹⁴ Adolf W. Karchmer,¹⁵ Carlos A. Mestres,¹⁶ Cathy A. Petti,^{1,17} Maria Nazarena Pizzi,¹⁸ Stephen D. Preston,¹⁹ Albert Roque,²⁰ Francois Vandenesch,^{21,22} Jan T. M. van der Meer,²³ Thomas W. van der Vaart,²³ and Jose M. Miro^{24,25}

Clin Infect Dis. 2023;77:518 and Clin Infect Dis. 2024; 78:964-967

2023 Duke-ISCVID Criteria for Diagnosis of Endocarditis

Definite Pathologic Diagnosis	Definite Clinical Diagnosis	Possible Clinical Diagnosis
Microorganisms identified on cardiac tissue, vegetation, graft, device	Two major criteria	Three minor criteria
OR	OR	OR
Vegetation, leaflet destruction, or adjacent cardiac tissue showing inflammatory changes	Five minor criteria	One major plus one minor criteria
	OR	
	One major plus three minor criteria	

Rejected endocarditis: criteria for definite or possible endocarditis are not met **OR** firm alternative diagnosis established **OR** lack of recurrence with < 4 days antibiotic therapy

SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION


2023 Duke-ISCVID Major Criteria

Positive Blood Cultures	Imaging	Surgical
Typical microorganisms* from 2 separate blood cultures OR Non-typical organisms in 3 or more separate blood cultures OR + PCR for <i>Coxiella burnetii</i>, <i>Bartonella</i>, <i>T. whipplei</i>; <i>Coxiella</i> phase I IgG antibody titer >1:800, IFA IgG titer for <i>Bartonella</i> ≥ 1:800	+ ECHO/Cardiac CT 1) Vegetation, leaflet perforation, aneurysm, abscess, pseudo-aneurysm, fistula OR 2) New regurgitation c/w prior imaging OR 3) NEW PVE dehiscence + PET/CT PV, device, or graft	Evidence of IE by direct inspection at surgery

**Staphylococcus aureus*, viridans group streptococci, *Streptococcus gallolyticus*, HACEK species (*Hemophilus* species, *Aggregatibacter*, *Cardiobacterium*, *Eikenella*, *Kingella*), *E. faecalis*, *S. lugdunensis*, *Granulicatella*, *Gamella*, *Abiotrophia* and in addition for PVE CoNS, *C. acnes*, *Corynebacterium*, *Serratia*

SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION

Role of Echocardiography



SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION

European Heart Journal (2015) 36, 3075–3123

2023 Duke-ISCVID Minor Criteria

- Predisposition: **previous IE**, PV, h/o valve repair, CHD, more than mild valve regurgitation or stenosis, CIED, hypertrophic cardiomyopathy, IVDU
- Fever, documented temperature $>38.0^{\circ}\text{C}$ ($>100.4^{\circ}\text{F}$)
- Vascular phenomena: systemic arterial emboli, septic pulmonary emboli, mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages, or Janeway lesions, **cerebral or splenic abscess**
- Immunologic phenomena: glomerulonephritis, Osler nodes, Roth spots, or rheumatoid factor
- Positive blood cultures that do not meet major criteria, OR **+PCR/NGS** for typical organism from sterile body site
 - **+ PET/CT of PV, graft, or device within 3 mo of implantation**
 - **New regurgitant murmur on exam and echocardiography unavailable**

Possible Endocarditis Rates with Duke Criteria

	2000 Criteria	2023 Criteria
% of all cases classified as possible	18-38	15-34
% of all possible cases that were true IE	41-52	30-36

Chambers, et al. Duke Infective Endocarditis Criteria 3.0 for the Clinician: Defining What Is Possible. Clin Infect Dis. 2024, in press

Native Valve Endocarditis

Question #2

A 63 y/o. man with no significant past medical history presents with a week of fever, rigors, and progressive dyspnea on exertion.

- Exam : BP 160/40 P110 , 39.5
 - Rales $\frac{1}{2}$ way up bilaterally
 - Loud diastolic decrescendo murmur, lower left sternal border
- Labs and studies
 - WBC 23,000 90% PMNS, HCT 30. Platelets 110.
 - Creatinine 1.6 mg/dL
 - TTE 1.5 cm oscillating mass, on bicuspid AV with severe aortic regurgitation
- 3/3 blood cultures: Gram positive cocci in clusters.

Question #2

What antibiotic regimen would you recommend pending further information about Gram-positive cocci?

- A. Nafcillin
- B. Vancomycin
- C. Vancomycin + nafcillin
- D. Vancomycin + gentamicin
- E. Vancomycin + gentamicin + rifampin

Native Valve Staph. aureus IE

Regimen	Duration	Comments
MSSA		
Nafcillin or oxacillin	6 wk	2-wk-uncomplicated R-sided IE (IDU)
Cefazolin	6 wk	Pen-allergic naf-intolerant patient
MRSA		
Vancomycin	6 wk	For MSSA if a beta-lactam cannot be used
Daptomycin	6 wk	10 mg/kg/day, vanco alternative

No gentamicin, no rifampin

SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION

Question #3

A 63-year-old woman with a history of mitral valve prolapse presents with 3 weeks of low-grade fever, fatigue, generalized weakness, weight loss, arthralgias. She is first chair violinist for the local orchestra.

- Exam: BP 135/90 P100 , 38.2°C
 - 3/6 holosystolic murmur, radiating the axilla
 - Lungs are clear, no peripheral stigmata of endocarditis
- Serum creatinine 1.2 mg/dl
- TTE: mitral valve prolapse with 0.5 cm vegetation on anterior leaflet, moderate regurgitation
- 3/3 blood cultures from admission positive for *Streptococcus mitis*, penicillin MIC = 0.25 µg/ml, ceftriaxone MIC = 0.25 µg/ml

Question #3

What antibiotic regimen would you recommend for definitive therapy of this patient's infection?

- A. Penicillin for 6 weeks
- B. Penicillin + gentamicin for 4 weeks
- C. Ceftriaxone for 4 weeks
- D. Penicillin + gentamicin for 2 weeks then penicillin for 2 weeks
- E. Ceftriaxone + gentamicin for 2 weeks then ceftriaxone for 2 weeks

Treatment of VGS and Strep. gallolyticus Native Valve Endocarditis

- Pen MIC $\leq$ 0.12 μ g/ml
 - Penicillin or ceftriaxone + gent x 2 weeks
 - Penicillin, ceftriaxone, vancomycin x 4 weeks
- Pen MIC > 0.12 μ g/ml, < 0.5 μ g/ml
 - Penicillin or ceftriaxone (4 wk) + gent (2 wk)
 - Ceftriaxone or vancomycin (4 wk)
- Pen MIC $\geq$ 0.5 μ g/ml (Gemella and nutritionally deficient species, Abiotrophia and Granulicatella)
 - Penicillin or ceftriaxone + gent
 - Vancomycin
 - Duration 4-6 weeks (two weeks of gent may be sufficient)

Question #4

A 72 y/o man type 2 diabetes mellitus, stage II chronic kidney disease (CKD), and a history of mild aortic stenosis is admitted to the hospital with fever, dysuria, and urinary frequency.

- Exam: T38.9°C, Pulse 110, BP 145/95 mm Hg
 - Lungs are clear
 - 3/6 systolic ejection murmur at the right upper sternal boarder
- Lab results
 - Serum glucose 340 mg/dl
 - Serum creatinine 1.7 mg/dl, BMP otherwise normal
 - UA: 3+ protein, 20-50 WBCs/high power field, 4+ glucose.
 - Two blood cultures and a urine culture are positive for ampicillin-susceptible *Enterococcus faecalis*

Question #4

What antibiotic regimen would you recommend for definitive therapy of this patient's infection?

- Ampicillin for 2 weeks
- Penicillin + gentamicin for 4 weeks
- Ampicillin + gentamicin for 4 weeks
- Ampicillin + ceftriaxone for 6 weeks
- Daptomycin for 8 weeks

Enterococcal Endocarditis

Regimen	Duration	Comments
Pen or amp + gent	4-6 wk	Pen S, Gent 1 mg/kg q8h, 6 wk for PVE, symptoms >3 mo*
Amp + ceftriaxone	6 wk	Pen S, aminoglycoside susceptible or resistant, <i>E. faecalis</i> only!
Pen or amp + strep	4-6 wk	Gent resistant, strep synergy, CrCl $\geq$ 50
Vanco + gent	6 wk	Pen resistant or beta-lactam intolerant (toxic!)
Linezolid or dapto	> 6 wk	VRE: Dapto 10-12 mg/kg & combo with amp or ceftaroline

*Limited data that 2 weeks of gent is sufficient

SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION

45 Endocarditis of Native and Prosthetic Devices, and Infections of Pacers and Ventricular Assist Devices

Speaker: Henry Chambers, MD

HACEK Organisms

- Haemophilus species
- Aggregatibacter species
- Cardiobacterium hominis
- Eikenella corrodens
- Kingella species

Antimicrobial Therapy of HACEK Endocarditis

Regimen	Comments
Ceftriaxone	Regimen of choice NO GENT: nephrotoxic
Levofloxacin	Levo or FQ as single agent OK as alternative regimen NO GENT: nephrotoxic
Ampicillin	Avoid: assume amp or pen resistant if no reliable MIC NO GENT: nephrotoxic

Empirical Therapy for Endocarditis While Awaiting Culture Results

- Vancomycin 60 mg/kg/d in divided doses + ceftriaxone 2 gm Q24h
- Severe penicillin allergy: Vancomycin + aztreonam 2 gm q8h

Oral Therapy of Endocarditis

POET Trial of Oral Therapy

- Noninferiority trial, 10% margin, left-sided endocarditis, IV vs partial oral
- Streptococci, Enterococcus faecalis, Staph. aureus (No MRSA), coag-negative staphylococci
- All patients given IV antibiotics for at least 10 days
- Primary outcome: composite of all-cause mortality, unplanned cardiac surgery, embolic events, or relapse within 6 mo

N Engl J Med 2019;380:415

Outcomes: POET Trial of Oral Therapy

1954 assessed
for eligibility

↓

1554 excluded
(428 no Duke criteria)



↓

400 randomized

Outcome	IV (N=199)	PO (N=201)
Mortality	13 (6.5%)	7 (3.5%)
Unplanned surgery	6 (3.0%)	6 (3.0%)
Embolic event	3 (1.5%)	3 (1.5%)
Relapse	5 (2.5%)	5 (2.5%)

N Engl J Med 2019;380:415

Outcomes: POET Trial of Oral Therapy



SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION

Culture-Negative Endocarditis

Question #5

A 37-year-old marginally housed man with a past history of injection drug use reports not feeling well for several weeks.

HPI: His reports intermittent fevers and thinks he has lost weight because clothes not longer fit him. He took a few doses of cephalexin given to him by a friend a couple of weeks ago which did not make much difference.

Exam: Tmax : 37.5°C/99.5°F; 2/6 systolic murmur on exam, otherwise WNL

Labs: CBC: mild normocytic anemia, hemoglobin 12 g/dL.
UA: 50-100 red cells per high-power field.
Serum creatinine: 3.6 mg/dL, high
C-reactive protein (CRP): 125 mg/L, high
C-ANCA (cytoplasmic antineutrophil antibody): positive
C3 complement: low
Blood cultures: negative at 96 hours

Question #5

What is the most likely diagnosis in this patient not feeling well for several weeks?

- A. Granulomatosis with polyangitis
- B. Culture-negative endocarditis due to *Staphylococcus aureus*
- C. Culture-negative endocarditis due to a viridans group streptococcal species
- D. Culture-negative endocarditis due to *Bartonella henselae*
- E. Culture-negative endocarditis due to *Tropheryma whippie*

Culture-Negative Endocarditis

- Prior antibiotics
- Fastidious organisms
 - HACEK
 - *Abiotrophia defectiva*, et al
- “Non-cultivable” organism
 - *Bartonella quintana* > *henselae*
 - *Coxiella burnetii*, *Tropheryma whippie*, *Legionella* spp.
- Fungi (molds)
- Not endocarditis
 - Libman-Sacks, myxoma, APLS, marantic

Culture-Negative Scenarios

- ***Coxiella burnetii* (Q fever):** Direct or indirect animal contact, hepatosplenomegaly, abnormal or prosthetic valve. Doxycycline + hydroxychloroquine >1 yr.
- ***Bartonella*:** Homeless, indolent, valve normal or abnormal, louse vector. **Rx:** Doxycycline 12 weeks plus rifampin first 6 weeks (or gent for the first 2 weeks)
- ***Tropheryma whippie*:** Indolent, protracted course with arthralgias, diarrhea, malabsorption, weight loss, CNS involvement

Tools for Diagnosis of Culture-Negative Endocarditis

Organism	Clinical clues	Serology	Specific PCR	Universal 16s/18s rRNA PCR, mNGS
HACEK, strep, etc	Prior antibiotics			X
Legionella spp.	Immunocompromise, PVE	X	X	X
T. whipplei	Chronic illness		X	X
Brucella spp.	Travel	X		X
Bartonella spp.	Cats, homeless, lice	X	X	X
Mycoplasma		X		X
Q fever	Animal contact, lab	X	X	X
Yeast, molds	Immunocompromised	X		X

mNGS = metagenomic next generation sequencing

SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION

Metagenomic Next Generation Sequencing




Figure 1. Microbial cell-free DNA testing process.

SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION

Clin Infect Dis. 2025 Jul 4;ciaf361. PMID 40614175

mNGS for Culture-negative Endocarditis

- Utility greatest when conventional microbiological studies are negative
- Unbiased, can detect rare non-cultivable pathogens
- Information provided: microorganism, DNA quantitation (molecules/100 nanoliter), resistance gene detection
- Concordant with blood cultures (provided the pathogen is in the database), remains positive up to a month or longer
- Clinical impact, good or bad, not well characterized; criteria lacking

mNGS for Culture-negative Endocarditis -Mayo Experience-

Diagnostic Categories		Endocarditis (66)	No Endocarditis (70)
Endocarditis	Definite	43	0
	Possible	23	41
	Rejected	0	29
mNGS+	CMT-	22 (33%)	20 (29%)
	CMT+	18 (27%)	0
mNGS-	CMT-	18 (27%)	50 (71%)
	CMT+	8 (12%)	0

Open Forum Infect Dis. 2025; 2:ofaf099. PMID 40046887

45 Endocarditis of Native and Prosthetic Devices, and Infections of Pacers and Ventricular Assist Devices

Speaker: Henry Chambers, MD

Prosthetic Valve and Device-Related Endocarditis

Question #6

A 72-year-old man s/p AV replacement with a bioprosthetic valve for bicuspid AV with insufficiency. He reports sore throat, cough, congestion, fever, chills, sweats and malaise for 3 days.

Exam: T 100.2o F, Pulse 85 , BP 130/70mm Hg, RR 16

HEENT: oral cavity and tonsils red and swollen, no lymphadenopathy

Lungs: clear

Heart: No murmur

Skin: no rash

Rapid mgs strep, rapid flu both negative

Question #6

What is the best approach for managing this patient?

- A. Obtain throat culture and prescribe Pen VK while awaiting results
- B. Obtain throat culture and give a script for Pen VK to be filled if culture is positive for GAS
- C. Prescribe azithromycin for treatment of acute URI
- D. Obtain blood cultures and await results
- E. Obtain blood cultures and initiate therapy with vancomycin, gentamicin, and rifampin

Diagnosis of PVE/TAVR

- Duke criteria and TEE less sensitive for PVE compared to native valve endocarditis
- PET-CT (¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography) plus mod Duke criteria*
 - Increased sensitivity: 84% vs. 57%
 - Reduced specificity: 71% vs 96%
- Multislice/Cardiac CT angiography similar to TEE in sensitivity and specificity, but added anatomic detail, useful if TEE non-diagnostic

*J Am Coll Cardiol Img 2020;13:2605
Clin Infect Dis 2021; 72:1687, Journal of Cardiology 2019; 73:126

Microbiology of PVE

Organisms	2 mo. Post-op (%)	2-12 mo. Post-op (%)	> 12 mo Post-op (%)
S. aureus	30	13	22
Streptococci	2	13	30
Enterococci	8	11	11
HACEK	0	0	4
CoNS	28	36	12
Gram-neg bacilli	10	4	5
Fungi	9	8	1
Culture-negative	6	6	10

Adapted from Karchmer and Chu, UpToDate, 2020

Antimicrobial Therapy of PVE/TAVR

Organism	Regimen	Duration
S. aureus, CoNS	Naf (MS) or vanco (MR) + gent + rif (add later)	Gent x 2 wk, naf/vanco + rif x 6 weeks
Streptococci, MIC $\leq$ 0.12 μ g/ml	Pen or ceftriaxone $\pm$ gent OR Vancomycin	6 weeks (optional gent, 1 st 2 wk) 6 weeks
Streptococci, MIC > 0.12 μ g/ml	Pen or ceftriaxone + gent OR Vancomycin	6 weeks 6 weeks
Enterococci	Same as for NVE	6 weeks

Cardiac Implantable Device Infections (Permanent pacemakers, defibrillators)

J Am Coll Cardiol 2008;49:1851; Circulation 2010;121:458; NEJM 2012;367:842; JAMA 2012;307:1727; Circulation 2024; 149:e201


Cardiac Implantable Device Infection Types

- Pocket site/generator only : ~ 60%
 - Blood culture positive <50%
 - Pocket infection or generator/lead erosion
- Occult bacteremia/fungemia: ~7-30%
- Lead infection +/- endocarditis: ~10-25%
- PET-CT may detect localized infection if work-up is inconclusive

45 Endocarditis of Native and Prosthetic Devices, and Infections of Pacers and Ventricular Assist Devices

Speaker: Henry Chambers, MD

Survival with and without Device Removal



SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION


Athan, JAMA. 2012; 307:1727-1735

AHA Guidelines for Management of Cardiac Implantable Device Infections

- Blood cultures before antibiotics
 - If positive, then TEE
- Gram stain, culture of pocket tissue, lead tips
- Device removal for all infections and occult staphylococcal bacteremia (consider for bacteremia with other endocarditis-causing organisms)
- Therapy (antibiotic based on susceptibility)
 - Pocket infection: 10-14 days
 - Bloodstream infection: ≥ 14 days
 - Lead or valve vegetations/endocarditis: 4-6 weeks

Circulation 2010;121:458-77


Algorithm for Management of an Infected Cardiac Implantable Device (CIED) Infection



THE NEW ENGLAND JOURNAL OF MEDICINE

Baddour LM et al. N Engl J Med 2012;367:842-849

Algorithm for Management of an Infected Cardiac Implantable Device (CIED) Infection




SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION

THE NEW ENGLAND JOURNAL OF MEDICINE

Baddour LM et al. N Engl J Med 2012;367:842-849

NEW Algorithm for Management of an Infected Cardiac Implantable Device (CIED) Infection



SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION



Circulation 2024; 149:e201

Can Defer CIED Extraction 2-4 Weeks If

- Suspected pocket infection** + negative blood cultures (before antibiotics) + implant < 3 mo + good response to oral antistaphylococcal antibiotic or PET/CT is negative
- No signs of pocket infection, suspected CIED infection** + negative blood cultures or if positive not *S. aureus* or CoNS and clears in 72 hours or TTE/TEE negative + PET/CT negative

Circulation 2024; 149:e201

Infection of Ventricular Assist Devices



Types of VAD Infections

- VAD-specific infections** – occurs only in LVAD patients
 - Pump pocket/cannula infections
 - Pocket infections
 - Driveline exit site infections (superficial or deep)
- VAD-related infections**- risk of LVAD infection increased
 - Bloodstream infections (VAD-related, IV catheter/non-VAD related)
 - Endocarditis (pump or cannula, native valve)
 - Mediastinitis, sternal wound infections
- Non-VAD infections**

Ann Cardiothoracic Surg 2021;10:233; Clinical Transplantation 2019;33:e13552.

Microbiology of VAD-Specific Infections

- *S. aureus*/coag-negative staphylococci
- *Pseudomonas aeruginosa*
- Enteric Gram-negatives
- Enterococci
- *Candida*

Clinical Transplantation 2019;33:e13552

Management and Therapy

- Initial empirical coverage for MRSA and *Pseudomonas aeruginosa*
- Pathogen-directed therapy when possible
- Chronic suppressive therapy to prevent relapse

Clinical Transplantation 2019;33:e13552;
Open Forum Infect Dis. 2020 Nov 16;8(1):ofaa532

Antimicrobial Therapy

Infection Type	Initial Therapy	Chronic Suppressive Therapy (Oral or IV)
BSI, non-L-VAD	IV, 2 wk	Probably not needed
BSI, L-VAD-related	IV, 6 wk	Expected
Mediastinitis	IV, 4-8 wk	Expected
Superficial driveline	Oral or IV, 2 wk	OK to stop, but may relapse
Deep driveline	IV, 2-8 wk depending on source control, BSI present	Expected
Pump pocket	IV, 4-8 wk, source control/device exchange	Expected unless device removed
Pump/cannula	IV, ≥ 6 wk, device exchange	Expected unless device removed

SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION

Clinical Transplantation 2019;33:e13552; Open Forum Infect Dis. 2020 Nov 16;8(1):ofaa532
Ann Cardiothoracic Surg 2021;10(2):233-239

IE Prophylaxis after Dental Procedures

YES

Prosthetic cardiac valve or material
Presence of cardiac prosthetic valve
Transcatheter implantation of prosthetic valves
Cardiac valve repair with devices, including annuloplasty, rings, or clips
Left ventricular assist devices or implantable heart
Previous, relapse, or recurrent IE
CHD
Unrepaired cyanotic congenital CHD, including palliative shunts and conduits
Completely repaired congenital heart defect with prosthetic material or device, whether placed by surgery or by transcatheter during the first 6 mo after the procedure
Repaired CHD with residual defects at the site of or adjacent to the site of a prosthetic patch or prosthetic device
Surgical or transcatheter pulmonary artery valve or conduit placement such as Melody valve and Contegra conduit
Cardiac transplant recipients who develop cardiac valvulopathy

SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION

NO

Implantable electronic devices such as a pacemaker or similar devices
Septal defect closure devices when complete closure is achieved
Peripheral vascular grafts and patches, including those used for hemodialysis
Coronary artery stents or other vascular stents
CNS ventriculoatrial shunts
Vena cava filters
Pledgets

Circulation. 2021;143:e963-e978

Which Dental Procedures?

YES

All dental procedures that involve manipulation of gingival tissue or the periapical region of teeth or perforation of the oral mucosa

NO

Anesthetic injections through noninfected tissue, taking dental radiographs, placement of removable prosthodontic or orthodontic appliances, adjustment of orthodontic appliances, placement of orthodontic brackets, shedding of primary teeth, and bleeding from trauma to the lips or oral mucosa

IE Prophylaxis Regimens

Situation	Agent	Adults	Children
Oral	Amoxicillin	2 g	50 mg/kg
Unable to take oral medication	Ampicillin OR	2 g IM or IV	50 mg/kg IM or IV
	Cefazolin or ceftriaxone	1 g IM or IV	50 mg/kg IM or IV
Allergic to penicillin or ampicillin—oral	Cephalexin*† OR	2 g	50 mg/kg
	Azithromycin or clarithromycin OR	500 mg	15 mg/kg
	Doxycycline	100 mg	<45 kg, 2.2 mg/kg >45 kg, 100 mg
Allergic to penicillin or ampicillin and unable to take oral medication	Cefazolin or ceftriaxone†	1 g IM or IV	50 mg/kg IM or IV

Single dose
30-60 min
before Procedure

SEE ENLARGED SLIDE FOLLOWING ENTIRE PRESENTATION

Main Take-home Points

- Duke-ISCVID criteria is a valuable tool for assessing the likelihood of endocarditis
- TTE is acceptable to rule out endocarditis if of high quality and in a low probability setting
- Use a tried-and-true regimen, avoid aminoglycoside combination therapy for NVE
- Think prior antibiotics and Bartonella in culture-negative endocarditis
- Any fever in a patient with a prosthetic valve is endocarditis until proven otherwise

45 Endocarditis of Native and Prosthetic Devices, and Infections of Pacers and Ventricular Assist Devices

Speaker: Henry Chambers, MD